Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/180634
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Egeberg, Alexander | - |
dc.contributor.author | Danø, Anne | - |
dc.contributor.author | Pedersen, Mikkel H. | - |
dc.contributor.author | Sohrt, Anne | - |
dc.contributor.author | Borg, Emma | - |
dc.contributor.author | Notario, Jaime | - |
dc.date.accessioned | 2021-10-18T07:04:41Z | - |
dc.date.available | 2021-10-18T07:04:41Z | - |
dc.date.issued | 2021-08-20 | - |
dc.identifier.issn | 1941-837X | - |
dc.identifier.uri | http://hdl.handle.net/2445/180634 | - |
dc.description.abstract | Aim: The purpose of this manuscript was to illustrate the impact of the place in the treatment sequence on the cost and cost-effectiveness of different biologics for patients with moderate-to-severe plaque psoriasis. Materials and methods: We developed a treatment sequence model and focused on seven different biological treatment options and 840 combinations of treatment sequences. The model converted cost of treatment to a cost per responder by dividing treatment cost by expected number of patients achieving PASI100 after 52 weeks of treatment. We used Spanish ex-factory price levels, dosing recommendations and real-world data on drug survival to calculate the treatment costs. Results: The most cost-effective treatment sequence was brodalumab-risankizumab-guselkumab-ixekizumab, with a cost per responder of €139,281 during the first five years of treatment. In comparison, if brodalumab was not recommended as first-line therapy, total costs would increase by 7.4% to €149,616. If brodalumab was not recommended as any of the first four lines of treatment, total costs would increase by 13.1% to €157,527 relative to the most cost-effective treatment sequence. Conclusions: A sequential therapy model may improve efficiency in the treatment of psoriasis. According to our results, brodalumab as the first-line therapy in Spain leads to the most cost-effective treatment sequence. | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Informa UK Limited | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1080/13696998.2021.1970953 | - |
dc.relation.ispartof | Journal of Medical Economics, 2021, vol. 24, num. 1, p. 1134-1142 | - |
dc.relation.uri | https://doi.org/10.1080/13696998.2021.1970953 | - |
dc.rights | cc by-nc-nd (c) Egeberg, Alexander et al, 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Psoriasi | - |
dc.subject.classification | Immunosupressors | - |
dc.subject.classification | Anàlisi cost-benefici | - |
dc.subject.other | Psoriasis | - |
dc.subject.other | Immunosupressive agents | - |
dc.subject.other | Cost effectiveness | - |
dc.title | Modelling the optimal sequence of biologic therapies in plaque psoriasis in Spain | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2021-10-14T08:46:32Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 34415224 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Modeling the optimal sequence of biologic therapies in plaque psoriasis in Spain.pdf | 722.46 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License